ATE494551T1 - C20orf23 als modifikator des igfr-wegs und verwendungsverfahren - Google Patents

C20orf23 als modifikator des igfr-wegs und verwendungsverfahren

Info

Publication number
ATE494551T1
ATE494551T1 AT05733099T AT05733099T ATE494551T1 AT E494551 T1 ATE494551 T1 AT E494551T1 AT 05733099 T AT05733099 T AT 05733099T AT 05733099 T AT05733099 T AT 05733099T AT E494551 T1 ATE494551 T1 AT E494551T1
Authority
AT
Austria
Prior art keywords
c20orf23
igfr
modifier
igfr pathway
pathway
Prior art date
Application number
AT05733099T
Other languages
English (en)
Inventor
Lori Friedman
Helen Francis-Lang
Annette Parks
Kenneth Shaw
Lynn Margaret Bjerke
Timothy S Heuer
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Application granted granted Critical
Publication of ATE494551T1 publication Critical patent/ATE494551T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
AT05733099T 2004-03-12 2005-03-10 C20orf23 als modifikator des igfr-wegs und verwendungsverfahren ATE494551T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55263404P 2004-03-12 2004-03-12
PCT/US2005/008127 WO2005090977A1 (en) 2004-03-12 2005-03-10 C20orf23 as modifier of the igfr pathway and methods of use

Publications (1)

Publication Number Publication Date
ATE494551T1 true ATE494551T1 (de) 2011-01-15

Family

ID=34993832

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05733099T ATE494551T1 (de) 2004-03-12 2005-03-10 C20orf23 als modifikator des igfr-wegs und verwendungsverfahren

Country Status (8)

Country Link
US (2) US7888047B2 (de)
EP (2) EP1723417B1 (de)
JP (2) JP2007528735A (de)
AT (1) ATE494551T1 (de)
AU (2) AU2005224620A1 (de)
CA (2) CA2559544A1 (de)
DE (1) DE602005025737D1 (de)
WO (2) WO2005090977A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1747462A2 (de) * 2004-04-27 2007-01-31 Galapagos N.V. Verfahren, agentien und screening-tests für verbindungen zur induktion der differenzierung undifferenzierter säugerzellen zu osteoblasten
US7953793B2 (en) 2009-01-08 2011-05-31 International Business Machines Corporation Distributed preboot execution environment (PXE) server booting
WO2013082275A1 (en) 2011-11-30 2013-06-06 Trustees Of Boston College Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1211313A3 (de) 2000-11-01 2003-04-23 Pfizer Limited Modulation der PDE11A-AKtivität
JP4917201B2 (ja) 2000-12-04 2012-04-18 株式会社リンフォテック 臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤、臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤、臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤ならびに臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤の製造方法。
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
EP2003196A3 (de) * 2003-06-09 2009-01-07 The Regents of the University of Michigan Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Krebs

Also Published As

Publication number Publication date
CA2559544A1 (en) 2005-09-29
EP1723415A4 (de) 2008-05-28
DE602005025737D1 (de) 2011-02-17
AU2005224614A1 (en) 2005-09-29
WO2005090977A1 (en) 2005-09-29
EP1723417A1 (de) 2006-11-22
US20090013416A1 (en) 2009-01-08
JP2007528735A (ja) 2007-10-18
US7888047B2 (en) 2011-02-15
US20090202563A1 (en) 2009-08-13
AU2005224620A1 (en) 2005-09-29
JP2007528734A (ja) 2007-10-18
US7943302B2 (en) 2011-05-17
EP1723417A4 (de) 2008-05-28
EP1723417B1 (de) 2011-01-05
CA2559543A1 (en) 2005-09-29
WO2005090976A1 (en) 2005-09-29
EP1723415A1 (de) 2006-11-22

Similar Documents

Publication Publication Date Title
ATE483976T1 (de) Gfats als modifikatoren des p53-wegs und verwendungsverfahren
WO2003074662A3 (en) SCDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
ATE489628T1 (de) Galk1s als modifikatoren des pten/akt-wegs
ATE536549T1 (de) Galnts als modifikatoren des igfr-weges und verwendungsverfahren
ATE494551T1 (de) C20orf23 als modifikator des igfr-wegs und verwendungsverfahren
WO2006009933A3 (en) Cdk9 as modifier of the igf pathway and methods of use
WO2005072475A3 (en) Itpks as modifiers of the igfr pathway and methods of use
WO2006036613A3 (en) Mracs as modifiers of the rac pathway and methods of use
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
ATE506614T1 (de) Gfats als modifikatoren des axin-wegs und verwendungsverfahren
WO2006009960A3 (en) Hdacs as modifiers of the rb pathway and methods of use
ATE469175T1 (de) Prkcs als modifikatoren des beta catenin pfads und anwendungsverfahren
WO2005090992A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2007058977A3 (en) Kifs as modifiers of the rho pathway and methods of use
WO2004015071A3 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004015072A3 (en) Mrbs as modifiers of the rb pathway and methods of use
WO2004061086A3 (en) Flj10607 as modifier of the axin pathway and methods of use
WO2004048536A3 (en) Rhebs as modifiers of the rb pathway and methods of use
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2005052131A3 (en) C140rf35 as modifier of the beta catenin pathway and methods of use
WO2004061123A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003074725A3 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
WO2005123111A3 (en) Maxs as modifiers of the axin pathway and methods of use
WO2004067721A3 (en) Tkts as modifiers of the beta-catenin pathway and methods of use
WO2004067722A3 (en) Facls as modifiers of the rb pathway and methods of use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties